Table 14.2.
In vitro and in vivo studies using chitosan-based nanoparticles in various cancer treatments
Drug/targeting | Chitosan-based composite | Experimental system, effects | Reference |
---|---|---|---|
Chemotherapeutic drug delivery | |||
Doxorubicin | CS-dextrane conjugate | Mice, AT, prolonged circulation | Mitra et al. (2001) |
Doxorubicin/trastuzumab | CS cross-linked by succinic anhydrate, Lys thiolation | SKOV-3 cells, AT, targets HER2+ receptors, enhanced uptake | Hebeish et al. (2013) |
Doxorubicin | CS-pluronic F127 micelles | MCF7 cells, AT, high drug loading capacity | Naruphontjirakul and Viravaidya-Pasuwat (2011) |
Doxorubicin/luteinizing hormone RH | CS-/poly(methyl vinyl ether maleic acid, magnetic nanoparticles | MCF7 cells, AT, increased cytotoxicity, targeting LHRH receptors | Varshosaz et al. (2016) |
Doxorubicin/folate | CS-coated magnetic nanoparticles | U87 cells in athymic mice, AT, guide by magnetic field, decreased tumor growth | Yang et al. (2017) |
Doxorubicin | Aluminosilicate zeolite (ZSM-5) CS core-shell nanodisks | Mice, AT, pH-dependent drug release, reduced Tu growth and increased apoptosis | Yang et al. (2018) |
Doxorubicin | CS-cobalt-ferrite-titanium oxide nanofibers | B16F10 cells, AT, fast drug release at low pH and alternating magnetic field | Radmansouri et al. (2018) |
Doxorubicin, verapamil/cRGD | Magnetic CS-poly(lactic acid-co-glycolic acid) nanoparticles | HepG2 and S-180 cells, Tu-bearing mice, AT, accumulation in tumor tissue | Shen et al. (2013a) |
Paclitaxel | Glycol-CS-β-cholanic acid nanoparticles | Tu-bearing mice, AT, impaired tumor growth after injection | Kim et al. (2006) |
Paclitaxel | CS-glyceryl monooleate core-shell nanopoparticles | MDA-MB-231cells, AT, 1000-fold reduction in IC50 | Trickler et al. (2008) |
Glycol-CS-β-cholanic acid nanoparticles | Tu-bearing mice, AT, impaired tumor growth after injection, EPR | Kim et al. (2008) | |
CS-polyaspartic acid sodium salt | Mice, sustained drug release in vitro and in vivo | Zheng et al. (2007) | |
5-Fluorouracil/hyaluronidase | CS-polyethylenglycol-gelatin copolymer | COLO-205 and HT-29 cells, AT, increased cytotoxicity by uptake and controlled drug release | Rajan et al. (2013) |
5-Fluorouracil | N-succinyl-CS-g-poly(acrylamide-co-acrylic acid) | Simulated gastric and intestinal fluids, efficient drug loading pH-dependent drug release | Bashir et al. (2017) |
5-Fluorouracil/ | cystamine conjugated CS- methoxy poly(ethylene glycol) | MCF7 cells, AT, improved hemocompatibility, high cytotoxicity to cancer cells | Antoniraj et al. (2018) |
TNF-α/anti-EGFR-2 | CS-silica hollow nanospheres | MCF-7 cells, AT, pH-dependent TNF-α release inside tumor | Deng et al. (2011b) |
Oxaliplatin/hyaluronic acid | CS nanoparticles encapsulated in Eudragit S100 coated pellets | Mice, HT-29 cells, AT, specific drug delivery in the colon | Jain et al. (2010) |
Trans-resveratrol/ , | CS nanoparticles | HepG2 cells, cytotoxicity highest when both, avidin and biotin, were coupled | Bu et al. (2013) |
/anti-EGFR, anti-chitosan | Glycol-CS nanobioconjugate | SW1990 cells, effective inhibition of cell proliferation, colony formation, migration, and invasion | Xiao and Yu (2017) |
Cancer gene therapy | |||
Survivin-siRNA/ | N-trimethyl CS-TPP developed for pulmonary delivery | A549 cells, bronchoalveolar lavage fluid, effective gene silencing of the survivin gene resulting in apoptosis | Ni et al. (2018) |
Midkine-siRNA | CS combined with 2-chloroethylamine and N,N-dimethyl-2-chloroethylamine hydrochloride | HepG2 cells, efficient transfection, significant decrease of cell proliferation | Zhong et al. (2015) |
psiRNA-hBCL2/dendrimeric RGD | Polyethyleneimine-g-CS | Tu-bearing mice, AT, efficient and specific transfection of tumor cells and silencing of anti-apoptotic hBcl2 | Kim et al. (2017) |
Ovalbumin | CS nanoparticles | Mice, AT, increased cytokine levels and stimulation of natural killer cells, deacreased tumor growth, detection of ovalalbumin specific cytotoxic T cells | Wen et al. (2011), Highton et al. (2016) |
IL-12 | CS nanoparticles | Mice, AT, activcation of cytotoxic T cells and natural killer cells, tumor regression, nor recurrence | Zaharoff et al. (2009) |
GRP | Mannosylated CS nanoparticles | Mice, intranasal application, AT, enhanced tumor regression paralleled by anti-GRP antibody production | Yao et al. (2013b) |
IP-10 plasmid/folate | CS nanoparticles | Mice, AT, inhibition of cell proliferation, induction of apoptosis, suppression of angiogenesis, and inactivation of regulatory T cells | Lai et al. (2014) |
AT anti-tumor effects, CS chitosan, Tu tumor